Literature DB >> 1895304

Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid.

G W Rewcastle1, G J Atwell, B C Baguley, M Boyd, L L Thomsen, L Zhuang, W A Denny.   

Abstract

A series of 16 analogues of the solid tumor active compound 9-oxo-9H-xanthene-4-acetic acid (XAA), with variations in the acetic acid side chain, have been prepared and evaluated for their ability to cause early haemorrhagic necrosis of colon 38 tumors in mice. The results extend the previous SAR for this class and confirm the necessity for a carboxylic acid group in a fixed disposition with respect to the xanthenone chromophore. None of the compounds showed superior potency to XAA itself, with virtually all alterations in the nature of the anionic center or its geometry with respect to the chromophore greatly reducing or abolishing activity. However, alpha-methylation of the side chain was permissible, and the two enantiomers of 5-methyl-alpha-methyl-XAA were separated and tested. Both were active, but the S-(+) enantiomer was much more dose-potent than the R-(-) enantiomer, in both the in vivo tumor necrosis assay and an in vitro assay measuring the stimulation of nitric oxide production by macrophages. This suggests that the enantiomers have different intrinsic activities, rather than differing in their vivo metabolism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1895304     DOI: 10.1021/jm00113a027

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

Review 1.  Vascular targeting agents.

Authors:  Mary Jo Pilat; Julie McCormick; Patricia Mucci LoRusso
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

Review 2.  Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?

Authors:  Marie Robin; Pierre Fenaux
Journal:  Leukemia       Date:  2020-07-13       Impact factor: 11.528

3.  Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis.

Authors:  Gonzalo Gutiérrez-García; Jesús Villarreal; Marta Garrote; Montserrat Rovira; Miquel Blasco; María Suárez-Lledó; Luis Gerardo Rodríguez-Lobato; Paola Charry; Laura Rosiñol; Pedro Marín; Alexandra Pedraza; María Teresa Solano; Carla Ramos; Noemí de Llobet; Miquel Lozano; Joan Cid; Carmen Martínez; Esteban Poch; Enric Carreras; Álvaro Urbano-Ispizua; Francesc Fernández-Avilés; A Pereira; Luis F Quintana
Journal:  Bone Marrow Transplant       Date:  2020-02-26       Impact factor: 5.483

4.  Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT.

Authors:  Yu Akahoshi; Satoshi Nishiwaki; Yasuyuki Arai; Kaito Harada; Yuho Najima; Yoshinobu Kanda; Katsuhiro Shono; Shuichi Ota; Takahiro Fukuda; Naoyuki Uchida; Souichi Shiratori; Masatsugu Tanaka; Junji Tanaka; Yoshiko Atsuta; Shinichi Kako
Journal:  Bone Marrow Transplant       Date:  2020-05-23       Impact factor: 5.483

5.  Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients.

Authors:  Mohamad Mohty; Domenico Russo; Nicola Polverelli; Paolo Tura; Giorgia Battipaglia; Michele Malagola; Simona Bernardi; Lisa Gandolfi; Tatiana Zollner; Camilla Zanaglio; Mirko Farina; Enrico Morello; Alessandro Turra
Journal:  Bone Marrow Transplant       Date:  2020-05-12       Impact factor: 5.483

Review 6.  Making the most of rodent tumour systems in cancer drug discovery.

Authors:  M C Bibby
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health.

Authors:  Daniel Wolff; Philipp Y Herzberg; Anne Herrmann; Steven Z Pavletic; Pia Heussner; Friederike Mumm; Christina Höfer; Inken Hilgendorf; Philipp G Hemmati; Ernst Holler; Hildegard Greinix; Sandra A Mitchell
Journal:  Bone Marrow Transplant       Date:  2020-07-31       Impact factor: 5.483

8.  Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.

Authors:  A L Laws; A M Matthew; J A Double; M C Bibby
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

9.  Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

Authors:  D R Newell; K M Searle; N B Westwood; S S Burtles
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

10.  Chiral Derivatives of Xanthones: Investigation of the Effect of Enantioselectivity on Inhibition of Cyclooxygenases (COX-1 and COX-2) and Binding Interaction with Human Serum Albumin.

Authors:  Carla Fernandes; Andreia Palmeira; Inês I Ramos; Carlos Carneiro; Carlos Afonso; Maria Elizabeth Tiritan; Honorina Cidade; Paula C A G Pinto; M Lúcia M F S Saraiva; Salette Reis; Madalena M M Pinto
Journal:  Pharmaceuticals (Basel)       Date:  2017-05-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.